Table 2.
Demonstrates the baseline characteristics and the morphologic endoscopic findings among the cysts sub-types
| IPMN | Other cyst types | |||||
|---|---|---|---|---|---|---|
| BD-IPMN | MD-IPMN | M-IPMN | MCN | SCA | PC | |
| Number of patients | 76 | 16 | 25 | 9 | 26 | 6 |
| Age (years), mean ± SD | 73.1 ± 10.6 | 73.9 ± 10.6 | 79.8 ± 8 | 65.4 ± 10.2 | 60.5 ± 15 | 57.2 ± 14.9 |
| Gender, N (%) | ||||||
|
Male Female |
26 (34.2) 50 (65.8) |
7 (43.7) 9 (56.3) |
16 (64) 9 (36) |
4 5 |
9 17 |
5 1 |
| Family history of pancreatic cancer, N (%) | 2 (2.6) | 0 | 0 | 0 | 0 | 1 (16.7) |
| Smoking, N (%) | 0 | 1 (6.2) | 5 (20) | 0 | 0 | 2 (33.3) |
| Background liver diseases, N (%) | ||||||
|
Cholestatic liver disease Other liver disease (HCV) |
0 5 (6.6) |
0 0 |
0 1 (4) |
0 0 |
0 0 |
0 0 |
| Personal history of cancer, N (%) | 16 (21) | 2 (12.5) | 4 (16) | 2 (22.2) | 2 (7.7) | 1 (16.7) |
| Alcohol consumption, N (%) | 1 (1.3) | 0 | 0 | 0 | 0 | 2 (33.3) |
| Gallbladder stone by EUS, N (%) | 15 (19.7) | 4 (25) | 4 (16) | 2 (22.2) | 1 (3.8) | 0 |
| Signs of chronic pancreatitis, N (%) | 0 | 1 (6.2) | 1 (4) | 0 | 0 | 2 (33.3) |
| Gallbladder in situ, N (%) | 64 (84.2) | 10 (62.5) | 19 (75) | 6 (66.7) | 26 (100) | 5 (83.3) |
| CBD dilation by EUS, N (%) | 14 (18.4) | 13 (81.2) | 7 (28) | 3 (33.3) | 1 (3.8) | 0 |
| CBD diameter by EUS (mm), mean ± SD | 6.3 ± 1.5 (3–7) | 9.3 ± 2.9 (7–16) | 7.1 ± 2.5 (5.2–17) | 7.1 ± 1.9 (6–10) | 6.1 ± 0.7 (6–9) | 6 (6) |
| Main pancreatic duct diameter by EUS (mm), mean ± SD | 2 ± 0.4 | 5.5 ± 1.9 | 4.8 ± 1.5 | 2.1 ± 0.5 | 1.9 ± 0.3 | 3.5 ± 1.2 |
| Amylase level (U/L), mean ± SD | 38,808 | 230,839 | 149,952 | 116 | 495 | 110,045 |
| CEA level (ng/mL), mean ± SD | 1764 | 39.2 | 252 | 1369 | 5.4 | 137 |